Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/2626
Title: | Risedronate reduces the risk of first vertebral fracture in osteoporotic women | Authors: | Heaney, RP Zizic, TM Fogelman, I Olszynski, WP GEUSENS, Piet Kasibhatla, C Alsayed, N. Isaia, G Davie, MW Chesnut, CH |
Issue Date: | 2002 | Publisher: | SPRINGER-VERLAG LONDON LTD | Source: | OSTEOPOROSIS INTERNATIONAL, 13(6). p. 501-505 | Abstract: | Risedronate treatment reduces the risk of vertebral fracture in women with existing vertebral fractures, but its efficacy in prevention of the first vertebral fracture in women with osteoporosis but without vertebral fractures has not been determined. We examined the risk of first vertebral fracture in postmenopausal women who were enrolled in four placebo-controlled clinical trials of risedronate and who had low lumbar spine bone mineral density (BMD) (mean T-score = -3.3) and no vertebral fractures at baseline. Subjects received risedronate 5 mg (77 = 328) or placebo (n = 312) daily for up to 3 years; all subjects were given calcium (1000 mg daily), as well as vitamin D supplementation (up to 500 IU daily) if baseline serum 25-hydroxyvitamin D levels were low. The incidence of first vertebral fracture was 9.4% in the women treated with placebo and 2.6% in those treated with risedronate 5 mg (risk reduction of 75%, 95% confidence interval 37% to 90%; P = 0.002). The number of patients who would need to be treated to prevent one new vertebral fracture is 15. When subjects were stratified by age, similar significant reductions were observed in patients with a mean age of 64 years (risk reduction of 70%, 95% CI 8% to 90%; P = 0.030) and in those with a mean age of 76 years (risk reduction of 80%, 95% CI 7% to 96%; P = 0.024). Risedronate treatment therefore significantly reduces the risk of first vertebral fracture in postmenopausal women with osteoporosis, with a similar magnitude of effect early and late after the menopause. | Notes: | Creighton Univ, Omaha, NE 68131 USA. Chesapeake Med Res, Baltimore, MD USA. Guys Hosp, London SE1 9RT, England. Midtown Med Ctr, Saskatoon, SK, Canada. Limburgs Univ Ctr, Diepenbeek, Belgium. Univ Hosp, Maastricht, Netherlands. Procter & Gamble Pharmaceut, Cincinnati, OH USA. Univ Turin, Turin, Italy. Charles Salt Ctr, Oswestry, Shrops, England. Univ Washington, Seattle, WA 98195 USA.Heaney, RP, Creighton Univ, 601 N 30th St,Suite 4841, Omaha, NE 68131 USA. | Keywords: | bone mineral density; osteoporosis; risedronate; vertebral fracture | Document URI: | http://hdl.handle.net/1942/2626 | ISSN: | 0937-941X | e-ISSN: | 1433-2965 | DOI: | 10.1007/s001980200061 | ISI #: | 000176689600010 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2003 |
Appears in Collections: | Research publications |
Show full item record
SCOPUSTM
Citations
68
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
53
checked on May 8, 2024
Page view(s)
58
checked on Jul 28, 2023
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.